drug
aspirin
Marketedupdated 5mo agoby $ASBP Aspire Biopharma Holdings, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE335 co-mentions · 107 sources
- tagApproval316 co-mentions · 104 sources
- drugSYNALGOS-DC288 co-mentions · 107 sources
- drugStem Cell Therapy for Coronavirus Disease 2019 (COVID-19)269 co-mentions · 107 sources
- tagSmall Molecule158 co-mentions · 104 sources
- drugcodeine94 co-mentions · 47 sources
- drugPROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE94 co-mentions · 47 sources
- drugPROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE94 co-mentions · 47 sources
all catalysts(0)
nothing on the calendar yet
Trials studying aspirin
- phase1Tegoprazan-Aspirin Drug Interaction in Healthy Adult Male Volunteers
- phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- phase3Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
- phase1A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants
- phase2Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
- N/AThromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
- phase1Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
- N/AHighest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 29, 2032
~6.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Sep 29, 2032formulationUS 10646431
- Sep 29, 2032formulationUS 10646431
- Sep 29, 2032method-of-use (U-3559)US 10786444
- Sep 29, 2032method-of-use (U-3559)US 10786444
- Sep 29, 2032formulationUS 9216150
- Sep 29, 2032method-of-use (U-1732)US 9226892
News(4)
- White House takes stock of US-based manufacturing for 86 essential drugsThe White House's Office of Management and Budget (OMB) is asking for more information on the domestic production of 86 essential medicines, such as the pain reliever aspirin and the blood pressure…endpoints · 5d ago
- Vaccines take center stage at federal autism advisory committeeComments about vaccines overshadowed an advisory committee meeting to discuss a plan for boosting federal funding for autism research.stat · 1mo ago
- Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC PreventionColton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.onclive · 4mo ago
- Predicting consequences of new hepatitis B vaccine recsNew data on public trust in science, AI and mental health, and other news from Morning Roundsstat · 5mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that